Toggle Nav

Vemurafenib (PLX4032, RG7204)

In stock
Catalog No.
BRAF kinase inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Vemurafenib is an inhibitor of BRAF kinase. It inhibits BRAFV600E and also has inhibitory activity in vitro against several other kinds of kinases, including CRAF, ARAF and wild-type BRAF. Vemurafenib is a competitive small-molecule serine–threonine kinase inhibitor that functions by binding to the ATP-binding domain of mutant BRAF. Vemurafenib can also give rise to activation of downstream MEK by normal RAF homo- and heterodimers in non-BRAF mutated cells, which has been shown to be caused by transactivation of the nondrug-bound partner in BRAF to CRAF heterodimers and CRAF to CRAF homodimers.


Keith. T Flaherty, Uma Yasothan and Peter Kirkpatrick. Vemurafenib. Nature Reviews Drug Discovery. 2011; 10: 811 – 812.

Jason J. Luke, F. Stephen Hodi. Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clinical Cancer Research. 2012; 18: 9 – 14.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
Cas No.918504-65-1
Solubility≥24.5mg/mL in DMSO
Chemical NameN-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
SDFDownload SDF
Canonical SMILESCCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.


Cell experiment:

Cell lines

MALME-3M melanoma cell lines

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

24 h; 10 μM


In melanoma cell lines, RG7204 was a potent inhibitor of proliferation in those expressing BRAFV600E but not BRAFWT. RG7204 also potently inhibited proliferation of melanoma cell lines expressing other codon 600 BRAF mutations (V600D, V600 K, and V600R).

Animal experiment:

Animal models

Athymic nude mice

Dosage form

100 mg/kg bid; oral taken.


In mice bearing Colo829 tumor xenografts, RG7204 at 100 mg/kg bid for 21 days showed greatly improved antitumor activity compared both with vehicle (P = 0.001) at the end of the study on day 38 after the tumor cell implant. There was complete tumor regression in all 10 mice treated with RG7204 by the end of the study. Survival in the mice treated with RG7204 was significantly better than in those treated with vehicle (P = 0.0008).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models[J]. Cancer research, 2010, 70(13): 5518-5527.

Biological Activity

Description Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM.
Targets B-RafV600E C-Raf MAP4K5 (KHS1) SRMS ACK1 FGR
IC50 31 nM 48 nM 51 nM 18 nM 19 nM 63 nM

Quality Control

Research Update

1. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012 Jul;342(1):33-40. doi: 10.1124/jpet.112.192195. Epub 2012 Mar 27.
Vemurafenib is a BRAF inhibitor that has been approved by FDA for the treatment of metastatic melanoma patients with a BRAF(V600E) mutation. Active efflux by P-gp and BCRP significantly restricted the brain distribution of vemurafenib at the blood-brain barrier, where active efflux by P-gp and BCRP restricted intracellular accumulation of vemurafenib and altered bidirectional net flux of vemurafenib.
2. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol. 2012 May;8(5):509-23. doi: 10.2217/fon.12.31.
Vemurafenib is a mutated BRAF kinase inhibitor that showed response rates of >50% in metastatic melanoma patients with BRAF mutation. In a Phase III study, the treatment of vemurafenib in previously untreated patients led to over survival of 84%, response rates of 48% and prolonged progression-free survival with largely reduced risk of death and disease progression.
4. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24;9:76. doi: 10.1186/1479-5876-9-76.
The combined MAPK oncogene inhibition and metabolic modulation of AMPK is an effective treatment of melanoma cells due to a molecular linkage between the MAPK and the LKB1-AMPK pathways.
5. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013 Aug;133(8):2041-9. doi: 10.1038/jid.2013.32. Epub 2013 Jan 23.
Although the treatment of vemurafenib, a Braf inhibitor, in melanoma patients with Braf(V600E) mutations resulted in dramatic improvement with decreased risk of death and tumor progression, melanoma cells rapidly acquire vemurafenib resistance, which can be overcome by targeting Stat3-PAX3 signaling pathway.